| Ytd | 50.80% | |
| 1y | 34.41% |
| Open | 10.89 | Prev Close | 10.86 | Low | 10.39 | High | 11.00 | Mkt Cap | 118.73M |
| Vol | 169.91K | Avg Vol | 244.64K | EPS | -7.53 | P/E | N/A | Forward P/E | N/A |
| Beta | 2.08 | Short Ratio | 0.11 | Inst. Own | 7.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-29 | 50-d Avg | 12.89 | 200-d Avg | 10.63 | 1yr Est | 19.15 |
KZIA News
Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-foc
Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurren
Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib P
BTIG analyst Kambiz Yazdi maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and raises the pr
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorecta
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorecta
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produce
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produce
Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Aug. 31, 2026 /P
Kazia's first 6 TNBC patients all achieved clinical benefits. These early results make paxalisib a m
Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-foc
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Com
Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market
Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-foc
SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Com
Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated
Kazia Therapeutics is rated Strong Buy, driven by best-in-class potential for paxalisib and a discou
Canaccord Genuity analyst John Newman initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with
Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing thera
Clinically relevant perioperative studies demonstrate elimination of residual disease and prevention
BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy ratin
Lake Street initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces
Mr. Levine brings more than two decades of experience across investment banking, executive and finan
SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Ther
Based on continued encouraging safety, tolerability and clinical activity data observed to date, pla
Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tol
SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology
SYDNEY, Australia, April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clini
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metas
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical u
SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chie
Novogen Limited (NASDAQ: KZIA - Get Free Report) was the target of a large drop in short interest du
Novogen (NASDAQ: KZIA - Get Free Report) and Opthea (NASDAQ: OPT - Get Free Report) are both small-c